WO2022265054A1 - 育毛剤 - Google Patents

育毛剤 Download PDF

Info

Publication number
WO2022265054A1
WO2022265054A1 PCT/JP2022/024020 JP2022024020W WO2022265054A1 WO 2022265054 A1 WO2022265054 A1 WO 2022265054A1 JP 2022024020 W JP2022024020 W JP 2022024020W WO 2022265054 A1 WO2022265054 A1 WO 2022265054A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
phytosphingosine
adenosine
growth
hair restorer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/024020
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
秀樹 高橋
荘太 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adjuvant Holdings Co Ltd
Original Assignee
Adjuvant Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adjuvant Holdings Co Ltd filed Critical Adjuvant Holdings Co Ltd
Priority to KR1020247001999A priority Critical patent/KR20240023618A/ko
Priority to US18/571,549 priority patent/US20240285501A1/en
Priority to JP2023530386A priority patent/JPWO2022265054A1/ja
Priority to CN202280055081.8A priority patent/CN117794505A/zh
Priority to TW111122676A priority patent/TW202317078A/zh
Publication of WO2022265054A1 publication Critical patent/WO2022265054A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions

Definitions

  • the present invention relates to a hair restorer. More particularly, it relates to a hair restorer containing phytosphingosine and adenosine.
  • Hair growth repeats growth and shedding according to a hair cycle (hair cycle) consisting of a growth phase, a regression phase, and a resting phase.
  • the symptoms of androgenetic alopecia are that the balance of the hair cycle is lost due to some cause, the period of growth period is shortened, the proportion of telogen hair is increased, and the hair becomes vellus (downy hair).
  • Histologically it has been reported that the size of anagen hair follicles is smaller than that of healthy scalp, the development of dermal papilla is poor, and the capillary network surrounding hair follicles is reduced (Non-Patent Document 1).
  • hair restorers that improve hair growth and hair type/hair quality.
  • active ingredients that contribute to the regulation of the hair cycle, which is the life cycle of hair, have been proposed and are being marketed as hair restorers.
  • vascular endothelial growth factor is a growth factor that acts specifically on vascular endothelial cells isolated from the culture medium of pituitary foliculo-stellate (stellate follicle) cells, and promotes the proliferation of vascular endothelial cells. It is known that adenosine promotes the angiogenesis process and enhances vascular permeability. It is clear that when adenosine acts on human dermal papilla cells, it promotes the expression of vascular endothelial growth factor (VEGF). (see Non-Patent Document 2).
  • Non-Patent Document 3 Adenosine has no reports of major side effects in human clinical trials, and the mechanism of improving thinning hair is not directly related to the regulation of sex hormones. has been proposed and put on the market (Non-Patent Document 3).
  • Phytosphingosine is known as a component of cosmetic raw materials (see Patent Document 1). However, there is no report on the hair growth effect of phytosphingosine.
  • An object of the present invention is to provide a hair restorer having an excellent hair growth effect.
  • the present inventors have conducted intensive studies to solve the above problems, and found that the use of phytosphingosine as an active ingredient can exhibit hair growth activity, and furthermore, the use of phytosphingosine and adenosine as active ingredients. As a result, the inventors have found that strong hair growth activity can be exhibited, and have completed the present invention.
  • the first means of the present invention for solving the above problems is a hair restorer characterized by containing phytosphingosine and adenosine as active ingredients.
  • the second means of the present invention for solving the above problems is a hair restorer for combined use with adenosine, characterized by containing phytosphingosine as an active ingredient.
  • a third means of the present invention for solving the above problems is a hair restorer for combined use with phytosphingosine, characterized by containing adenosine as an active ingredient.
  • the fourth means of the present invention for solving the above problems is the hair restorer according to any one of the first to third means of the present invention, which is used for promoting hair shaft growth or hair growth. is.
  • a fifth means of the present invention for solving the above-mentioned problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for improving hair shaft elongation speed. is.
  • the sixth means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for improving the maximum length of hair shafts. is.
  • the seventh means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for increasing the diameter of the hair shaft. be.
  • the eighth means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for increasing the number of hairs. .
  • the ninth means of the present invention for solving the above problems is the hair restorer according to any one of the first to eighth means of the present invention, which is a solution.
  • a tenth means of the present invention for solving the above problems is the hair restorer according to any one of the first to ninth means of the present invention for hair, bristles, eyebrows and/or eyelashes. is an agent.
  • the eleventh means of the present invention for solving the above problems is a method for producing a hair restorer, characterized by having a step of incorporating phytosphingosine and adenosine into a formulation as active ingredients.
  • the twelfth means of the present invention for solving the above problems is a method for producing a hair restorer for combined use with adenosine, characterized by including a step of incorporating phytosphingosine as an active ingredient into a formulation.
  • the thirteenth means of the present invention for solving the above problems is a method for producing a hair restorer for combined use with phytosphingosine, characterized by including a step of incorporating adenosine as an active ingredient into a formulation.
  • a fourteenth means of the present invention for solving the above problems is a hair restorer kit containing a formulation containing phytosphingosine and a formulation containing adenosine.
  • a fifteenth means of the present invention for solving the above problems is a hair restorer kit for combined use with adenosine, which contains a formulation containing phytosphingosine.
  • the sixteenth means of the present invention for solving the above problems is a hair restorer kit for combined use with phytosphingosine, which contains an adenosine-containing preparation.
  • the seventeenth means of the present invention for solving the above problems is a hair growth method characterized by administering phytosphingosine and adenosine as active ingredients.
  • An eighteenth means of the present invention for solving the above problems is a hair restoration method comprising administering the hair restorer according to any one of the first to tenth means of the present invention to a subject. .
  • Another means of the present invention for solving the above problems is a scalp care agent containing phytosphingosine and adenosine as active ingredients.
  • Another means of the present invention for solving the above problems is a method for improving scalp symptoms including administering to a subject a scalp care agent containing phytosphingosine and adenosine as active ingredients.
  • VEGF production promoter for dermal papilla cells containing phytosphingosine and adenosine as active ingredients.
  • phytosphingosine and adenosine are contained or used in combination as active ingredients in a hair restorer that is an external preparation to promote hair shaft growth in hair such as head hair, pubic hair, eyebrows and/or eyelashes.
  • a hair restorer that is an external preparation to promote hair shaft growth in hair such as head hair, pubic hair, eyebrows and/or eyelashes.
  • FIG. 1 is a graph showing changes in the expression level of VEGF gene in human dermal papilla cells by stimulation with adenosine, phytosphingosine, and phytosphingosine and adenosine for 72 hours.
  • the active ingredients of the hair restorer and scalp care agent according to the present invention contain both phytosphingosine and adenosine, or contain phytosphingosine and adenosine in combination.
  • the concentration of phytosphingosine and adenosine, which are active ingredients in the hair restorer and scalp care agent of the present invention is 0.001 to 20% by weight relative to the total hair restorer and scalp care agent. More specifically, it is 0.005 to 10% by weight.
  • the hair restorer and scalp care agent of the present invention are pharmaceuticals, quasi-drugs, cosmetics including cosmetics for hair, lashes, eyebrows and/or eyelashes, and cosmetics for the scalp, and ointments, cataplasms, liniments, lotions, and liquids for external use. , dusting agents, creams, gels, milky lotions, hair tonics, hair sprays, microneedles, etc., and can be used as preparations having various dosage forms such as, but not limited to, these.
  • the hair restorer and scalp care agent of the present invention can be produced through a process of incorporating phytosphingosine and adenosine as active ingredients.
  • the hair restorer and scalp care agent for combined use with adenosine of the present invention are obtained by a step of incorporating phytosphingosine as an active ingredient, and the hair restorer and scalp care agent for combined use with phytosphingosine are , and adenosine as an active ingredient.
  • a step of adding additives for formulation may be added.
  • the dosage forms of these preparations are the same dosage form, but a combination of different dosage forms. It can also be provided as a kit for providing formulations of those dosage forms.
  • Components of these additives include, for example, excipients, stabilizers, flavoring agents, bases, dispersants, diluents, anionic surfactants, amphoteric surfactants, nonionic surfactants, cationic surfactants, Active agents, anionic polymers, nonionic polymers, ethylene oxide/propylene oxide block copolymers, alcohols, emulsifiers, percutaneous absorption enhancers, pH adjusters, preservatives, coloring agents, oils and fats, mineral oils, etc.
  • the hair restorer and scalp care agent of the present invention may further contain known ingredients having effects such as hair growth, hair restoration, and hair nourishing.
  • the dosage of the active ingredient per administration of the hair restorer and scalp care agent in the means of the present invention can be adjusted so that the effects of the hair restorer and scalp care agent of the present invention are exhibited.
  • the dosage can be, for example, 0.005 to 200 mg, specifically 0.05 to 100 mg, and more specifically 0.5 to 10 mg.
  • the administration frequency of the hair restorer and scalp care agent of the present invention can be once or multiple times so that the effects of the hair restorer and scalp care agent of the present invention are exhibited.
  • the frequency of administration of the hair restorer and scalp care agent of the present invention can be, for example, 1 to 6 times per day. Specifically, it can be 1 to 3 times per day, more specifically 1 to 2 times per day.
  • the hair restorer and scalp care agent of the present invention relate to promotion of hair shaft growth, hair growth and prevention of hair loss, preferably promotion of hair shaft growth and hair growth.
  • promoting hair shaft growth means improving the hair shaft elongation speed, improving the maximum hair shaft length, and/or increasing the hair shaft diameter.
  • hair growth means that hair growth has stopped at a site where hair does not grow (the hair shaft does not protrude from the epidermis) or where the number of hairs is small, or the ability to grow hair is reduced. It means to promote the growth of new hairs from the pores to increase the number of hairs, in particular, to shorten the resting phase in the hair cycle and / or to restart the stopped hair cycle. .
  • having a hair shaft growth promoting effect means acting favorably on hair shaft growth promotion, and the property showing the hair shaft growth promoting effect is referred to as “hair shaft growth promoting activity”.
  • has a hair growth effect means that it acts favorably on hair growth, and the property showing the hair growth effect is referred to as “hair growth promoting activity”.
  • hair loss refers to a phenomenon in which hair shafts fall out of pores, and specifically refers to an increase in inhibitory cytokines that inhibit cell proliferation and cell death. Attributes that demonstrate anti-hair loss efficacy are referred to as "anti-hair loss activity.”
  • anti-hair loss activity Attributes that demonstrate anti-hair loss efficacy are referred to as "anti-hair loss activity.”
  • the term “has an anti-hair loss effect” means that the number of hair shafts falling out from pores is reduced through the inhibition or reduction of inhibitory cytokines and the suppression of cell death. It is a physiological phenomenon that is different from the attribute that indicates the hair effect.
  • scalingp symptoms means symptoms such as dandruff, rough skin, dry scalp, erythema, itching, and pimples.
  • scaling symptom improvement means suppression or improvement of dandruff, rough skin, dryness of the scalp, erythema, itching, pimples, and the like.
  • the hair restorer of the present invention can be used to improve the elongation speed of hair shafts or the maximum length of hair shafts. Then, the hair shaft elongation speed can be improved, for example, by about 110% at maximum, and specifically by about 25 to 110%, compared to the hair shaft elongation speed in the standard data of the hair cycle. More specifically, it can be improved by about 33 to 110%.
  • the maximum length of the hair shaft can be improved, for example, by about 49% at maximum, specifically by about 1 to 49%, compared to the maximum length of the hair shaft in the standard data of the hair cycle. More specifically, it can be improved by about 2 to 49%.
  • the hair restorer of the present invention can be used to increase the diameter of hair shafts.
  • the hair restorer of the present invention causes new hairs to grow from pores where hair growth has stopped (no hair shafts protrude from the epidermis) or where there are few hairs, or where hair growth ability has decreased. It can be used to promote hair growth to increase hair number, and in particular can be used to shorten the telogen phase in the hair cycle and/or to restart stopped hair cycles.
  • the hair restorer and scalp care agent of the present invention can be used not only for humans but also for animals such as livestock and pets.
  • a hair growth method and a scalp symptom amelioration method comprising administering an external preparation containing phytosphingosine and adenosine to subjects including humans and non-human animals such as livestock and pets.
  • the VEGF gene is expressed in dermal papilla cells and exhibits effects such as promotion of hair shaft growth, improvement in hair shaft elongation speed, improvement in maximum hair shaft length, and increase in hair shaft diameter in head hair, bristles, eyebrows and/or eyelashes. is said to contribute to Therefore, human dermal papilla cells were used to evaluate the enhancement of VEGF gene expression in each component.
  • Human dermal papilla cells and medium Human dermal papilla cells (catalog number: CA60205a, Caucasian, 29-year-old male, Toyobo Co., Ltd. (Japan)) were purchased and prepared as described in the protocol. We maintained and cultured the cells and performed test evaluations.
  • the FastGene RNA Basic Kit (catalog number: FG-80250, Nippon Genetics Co., Ltd. (Japan)) was used to collect total RNA from the cells.
  • 300 ⁇ L of lysis buffer RL was added per well, and the cells were lysed by pipetting. 300 ⁇ L of 70% ethanol was added to the cell lysate and mixed by pipetting. The sample solution was added to the FastGene RNA binding column and centrifuged at 10000 rpm for 1 minute at room temperature. After discarding the filtrate that passed through the column from the collection tube and returning the FastGene RNA binding column to the original collection tube, 600 ⁇ L of washing buffer RW1 was added to the FastGene RNA binding column and centrifuged at 10000 rpm for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube and set, 700 ⁇ L of washing buffer RW2 was added to the FastGene RNA binding column, and centrifuged at 10000 rpm for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube, set, and centrifuged at 15000 rpm for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube and set, 50 ⁇ L of elution buffer RE was added to the center of the membrane of the FastGene RNA binding column, and centrifuged at 10000 rpm for 1 minute at room temperature to collect the purified RNA.
  • the concentration of the collected RNA was measured with NanoDrop Lite (catalog number: ND-LITE, Thermo Fisher Scientific Co., Ltd.) and stored at -80°C until the next cDNA conversion.
  • FastGene scriptase II cDNA synthesis 5x Ready Mix (catalog number: NE-LS64, Nippon Genetics Co., Ltd. (Japan)) was used for cDNA synthesis.
  • the total RNA produced in a new tube was diluted with RNase-Free Water so that the concentration was 20 ng/mL, and 4 ⁇ L of FastGene scriptase II cDNA synthesis 5 ⁇ Ready Mix was added to 16 ⁇ L of this sample solution and vortexed.
  • a MiniAmp thermal cycler Thermo Fisher Scientific Co., Ltd.
  • the cDNA synthesized by the above method was used for real-time PCR.
  • Add each cDNA template dilution to a predetermined well of a 96-well plate, add THUNDERBIRD SYBR qPCR Mix (catalog number: QPS-201, Toyobo Co., Ltd. (Japan)) and primers, mix, and mix with QuantStudio 7 Flex Real - Gene expression was analyzed with Time PCR System (catalog number: 4485693, Thermo Fisher Scientific Co., Ltd.).
  • As a PCR reaction 40 cycles of 95°C for 5 seconds, 60°C for 30 seconds, and 72°C for 30 seconds were performed.
  • VEGF gene-specific primers used in the test and the GAPDH gene-specific primers used as internal standards are shown below.
  • Primer for detecting VEGF gene expression Forward direction: aggccagcacataggagaga (SEQ ID NO: 1) Reverse: acgcgagtctgtgttttgc (SEQ ID NO: 2)
  • Primer for detecting GAPDH gene expression Forward direction: catccctgcctctactggcgctgcc (SEQ ID NO: 3)
  • the relative expression level of each gene was calculated as follows.
  • the Ct value (PCR cycle number) was calculated from the intersection of the amplification curve of each gene and the threshold line.
  • the value obtained by dividing the Ct value of the target gene by the Ct value of the internal standard GAPDH gene is the relative expression level.
  • phytosphingosine enhances the expression of the VEGF gene in dermal papilla cells, promotes hair shaft growth in hairs such as scalp hair, bristles, eyebrows and/or eyelashes, improves hair shaft elongation speed, and increases the maximum hair shaft length. It was confirmed that it is useful as an active ingredient of a hair restorer and a scalp care agent that have the effect of improving the hair shaft diameter and increasing the diameter of the hair shaft.
  • the expression of the VEGF gene in dermal papilla cells is significantly and markedly enhanced, and adenosine is used in combination. It has the effect of enhancing the hair-growth effect, promoting hair shaft growth, improving the speed of hair shaft elongation, improving the maximum length of the hair shaft, and further increasing the diameter of the hair shaft in hair such as hair, pubic hair, eyebrows and/or eyelashes. It was confirmed that it is useful as an active ingredient for hair restorers and scalp care agents.
  • a hair restorer containing both phytosphingosine and adenosine, or a combination of phytosphingosine and adenosine, as an active ingredient of a hair restorer can be used for hair, bristles, eyebrows and/or eyelashes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2022/024020 2021-06-19 2022-06-15 育毛剤 Ceased WO2022265054A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020247001999A KR20240023618A (ko) 2021-06-19 2022-06-15 육모제
US18/571,549 US20240285501A1 (en) 2021-06-19 2022-06-15 Hair growth agent
JP2023530386A JPWO2022265054A1 (https=) 2021-06-19 2022-06-15
CN202280055081.8A CN117794505A (zh) 2021-06-19 2022-06-15 育毛剂
TW111122676A TW202317078A (zh) 2021-06-19 2022-06-17 育毛劑

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021102089 2021-06-19
JP2021-102089 2021-06-19

Publications (1)

Publication Number Publication Date
WO2022265054A1 true WO2022265054A1 (ja) 2022-12-22

Family

ID=84527546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/024020 Ceased WO2022265054A1 (ja) 2021-06-19 2022-06-15 育毛剤

Country Status (6)

Country Link
US (1) US20240285501A1 (https=)
JP (1) JPWO2022265054A1 (https=)
KR (1) KR20240023618A (https=)
CN (1) CN117794505A (https=)
TW (1) TW202317078A (https=)
WO (1) WO2022265054A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025143187A1 (ja) * 2023-12-28 2025-07-03 株式会社 資生堂 アデノシン含有目元用化粧料

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6425712A (en) * 1987-04-28 1989-01-27 Lion Corp Composition for hair
JPH04124122A (ja) * 1990-09-14 1992-04-24 Shiseido Co Ltd 白髪防止黒化剤
JPH09227343A (ja) * 1996-02-15 1997-09-02 L'oreal Sa ２−アミノ−１，３−アルカンジオールを含有する、髪抜け遅延および／または髪成長誘発および刺激剤
JPH09241156A (ja) * 1996-03-06 1997-09-16 Noevir Co Ltd 血流促進剤及びこれを配合して成る皮膚外用剤
JP2008247754A (ja) * 2007-03-29 2008-10-16 Shiseido Co Ltd 外用組成物
JP2014240381A (ja) * 2013-05-15 2014-12-25 ライオン株式会社 プレシャンプー型毛髪処理剤組成物
JP2015178485A (ja) * 2014-02-25 2015-10-08 株式会社コーセー 育毛用組成物
JP2016520546A (ja) * 2013-04-04 2016-07-14 ピトス カンパニー リミテッド 新規なフィトスフィンゴシン−１−リン酸誘導体、その調製方法、およびそれを含む脱毛の予防、治療、または育毛用組成物
WO2022107866A1 (ja) * 2020-11-19 2022-05-27 株式会社アジュバンホールディングス 育毛剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3220434B2 (ja) 1998-12-28 2001-10-22 花王株式会社 化粧料
WO2015114176A1 (es) * 2014-01-31 2015-08-06 Dermopartners, S.L. Producto cosmético con propiedades contra el envejecimiento de la piel
KR101800956B1 (ko) * 2016-04-04 2018-01-25 주식회사 와이제이테크 파이토스핑고신과 효모추출물을 유효성분으로 포함하는 탈모방지 및 발모촉진용 조성물
US20240139276A1 (en) * 2021-02-26 2024-05-02 Adjuvant Holdings Co., Ltd. Hair growth agent
US20240285502A1 (en) * 2021-06-19 2024-08-29 Adjuvant Holdings Co., Ltd. Hair growth agent
WO2022265052A1 (ja) * 2021-06-19 2022-12-22 株式会社アジュバンホールディングス 育毛剤

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6425712A (en) * 1987-04-28 1989-01-27 Lion Corp Composition for hair
JPH04124122A (ja) * 1990-09-14 1992-04-24 Shiseido Co Ltd 白髪防止黒化剤
JPH09227343A (ja) * 1996-02-15 1997-09-02 L'oreal Sa ２−アミノ−１，３−アルカンジオールを含有する、髪抜け遅延および／または髪成長誘発および刺激剤
JPH09241156A (ja) * 1996-03-06 1997-09-16 Noevir Co Ltd 血流促進剤及びこれを配合して成る皮膚外用剤
JP2008247754A (ja) * 2007-03-29 2008-10-16 Shiseido Co Ltd 外用組成物
JP2016520546A (ja) * 2013-04-04 2016-07-14 ピトス カンパニー リミテッド 新規なフィトスフィンゴシン−１−リン酸誘導体、その調製方法、およびそれを含む脱毛の予防、治療、または育毛用組成物
JP2014240381A (ja) * 2013-05-15 2014-12-25 ライオン株式会社 プレシャンプー型毛髪処理剤組成物
JP2015178485A (ja) * 2014-02-25 2015-10-08 株式会社コーセー 育毛用組成物
WO2022107866A1 (ja) * 2020-11-19 2022-05-27 株式会社アジュバンホールディングス 育毛剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025143187A1 (ja) * 2023-12-28 2025-07-03 株式会社 資生堂 アデノシン含有目元用化粧料

Also Published As

Publication number Publication date
CN117794505A (zh) 2024-03-29
JPWO2022265054A1 (https=) 2022-12-22
US20240285501A1 (en) 2024-08-29
KR20240023618A (ko) 2024-02-22
TW202317078A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
WO2022265053A1 (ja) 育毛剤
KR20060123256A (ko) 모발의 태모화 방법 및 조성물
WO2022265054A1 (ja) 育毛剤
WO2022265052A1 (ja) 育毛剤
WO2022181786A1 (ja) 育毛剤
FR2984129A1 (fr) Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
WO2022181785A1 (ja) 育毛剤
JP7291333B2 (ja) 育毛剤
HK40102132A (zh) 育毛剂
HK40102133A (zh) 育毛剂
HK40092879A (zh) 育毛剂
HK40101945A (zh) 育毛剂
KR102035812B1 (ko) 모발 성장 촉진제
WO2025084438A1 (ja) 硫酸転移酵素産生促進剤および硫酸転移酵素活性促進剤
JP2022551825A (ja) 皮膚微生物叢の多様性を増加させるためのｎ－メチルグリシンの新規化粧使用
US10543227B2 (en) Hair growth composition
JP7853727B2 (ja) ２型アルデヒド脱水素酵素の調節による脱毛または白毛の予防、改善、または治療用組成物
JP2004331664A (ja) ピリミジン−ｎ−オキシド誘導体を含有する毛髪用組成物、ケラチン繊維の成長を刺激し及び／又は抜毛を減少させるためのその使用
HK40092880A (zh) 育毛剂
JP2023025132A (ja) スカルプケア剤
JP3624318B2 (ja) 養毛剤
WO2022124212A1 (ja) 毛髪改善のための組成物
JP2025503964A (ja) ２型アルデヒド脱水素酵素の調節による脱毛または白毛の予防、改善、または治療用組成物
FR3156650A1 (fr) Composition cosmétique comprenant un composé apte à inhiber l’enzyme FIH-1 et un composé apte à inhiber l’enzyme PHD2 pour le traitement de la chute5 des cheveux
EP2465581B1 (en) Non-therapeutic use of a composition for promoting hair growth

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22825042

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023530386

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2301008232

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 18571549

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 12023553454

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 20247001999

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020247001999

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202280055081.8

Country of ref document: CN

122 Ep: pct application non-entry in european phase

Ref document number: 22825042

Country of ref document: EP

Kind code of ref document: A1